For adults with von Willebrand disease (VWD)

VONVENDI®
is in
your
corner

The first and only recombinant von Willebrand factor (VWF)1, VONVENDI was engineered for the treatment of VWD.2 It works similarly to the body’s naturally occurring VWF.2

In a clinical study, VONVENDI was proven to treat and control bleeds when given as needed—or on demand.2

VONVENDI was also shown to prevent excessive bleeding during and after surgery.2 In the study, VONVENDI was given before and after major, minor, and oral surgeries.2

Talk to your doctor about VONVENDI, and whether it might be right for you.

If you are looking for a doctor with experience treating VWD, a hemophilia treatment center is staffed with health professionals familiar with treating bleeding disorders.

The first and only recombinant von Willebrand factor (VWF)1, VONVENDI was engineered for the treatment of VWD.2 It works similarly to the body’s naturally occurring VWF.2

In a clinical study, VONVENDI was proven to treat and control bleeds when given as needed—or on demand.2

VONVENDI was also shown to prevent excessive bleeding during and after surgery.2 In the study, VONVENDI was given before and after major, minor, and oral surgeries.2

Talk to your doctor about VONVENDI, and whether it might be right for you.

If you are looking for a doctor with experience treating VWD, a hemophilia treatment center is staffed with health professionals familiar with treating bleeding disorders.

LEARN MORE

To see if VONVENDI might be right for you, talk with your doctor or call 1-866-424-6724 to speak with a Senior Clinical Specialist.

RESOURCES & ASSISTANCE

Image of three dosing vials: Download the registration form for the free trial program

Free Trial Program

Through Takeda’s FREEDOM OF CHOICE™ Free Trial Program, patients may be eligible to receive 3 free doses of VONVENDI.*

*Free Trial Program is for new VONVENDI patients only. Participants must receive consultation and approval from a healthcare provider.

Download Registration Form
Icon of the dollar symbol: Co-pay assistance for eligible patients

CoPay Assistance

Financial assistance is available for eligible patients through Takeda’s CoPay Assistance Program.

Enroll Now

References: 1. Baxalta receives FDA Approval for VONVENDI, the first and only recombinant treatment for adults affected by von Willebrand disease. Business Wire website. https://www.businesswire.com/news/home/20151208006689/en/Baxalta-Receives-FDA-Approval-VONVENDIRecombinant- Treatment. Published December 8, 2015. Accessed March 11, 2019. 2. VONVENDI [von Willebrand factor (Recombinant)] Prescribing information. Lexington, MA.